Cellebrite DI (NASDAQ:CLBT) Upgraded by Wall Street Zen to Buy Rating

Key Points

• Cellebrite DI (NASDAQ:CLBT) was upgraded from a "hold" to a "buy" rating by Wall Street Zen, indicating positive investor sentiment towards the company's stock.
• Despite Needham & Company and JPMorgan reducing their price targets, the stock still holds an average rating of "Buy" with a consensus price target of $21.00.
• The company's recent earnings report showed a positive performance, with $0.12 earnings per share, exceeding the expected $0.11, and an 18.4% year-over-year revenue increase to $113.28 million.

Wall Street Zen upgraded shares of Cellebrite DI (NASDAQ:CLBT - Free Report) from a hold rating to a buy rating in a research note released on Saturday.

Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. lowered their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Lake Street Capital lowered their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Finally, Needham & Company LLC lowered their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Cellebrite DI currently has an average rating of "Buy" and a consensus price target of $22.40.

Cellebrite DI Price Performance

Cellebrite DI stock traded down $0.2850 during mid-day trading on Friday, reaching $15.5150. The stock had a trading volume of 148,088 shares, compared to its average volume of 1,664,228. The company has a market capitalization of $3.72 billion, a price-to-earnings ratio of -20.49, a PEG ratio of 3.20 and a beta of 1.27. The company has a 50-day moving average price of $14.96 and a two-hundred day moving average price of $17.67. Cellebrite DI has a one year low of $13.10 and a one year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to analysts' expectations of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business's revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts anticipate that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bosun Asset Management LLC increased its holdings in Cellebrite DI by 1.4% in the 4th quarter. Bosun Asset Management LLC now owns 43,307 shares of the company's stock worth $954,000 after acquiring an additional 584 shares in the last quarter. OneDigital Investment Advisors LLC increased its holdings in Cellebrite DI by 2.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock worth $556,000 after acquiring an additional 688 shares in the last quarter. Signaturefd LLC increased its holdings in Cellebrite DI by 68.3% in the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company's stock worth $32,000 after acquiring an additional 819 shares in the last quarter. TD Waterhouse Canada Inc. increased its holdings in Cellebrite DI by 1.8% in the 4th quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company's stock worth $1,046,000 after acquiring an additional 859 shares in the last quarter. Finally, SkyView Investment Advisors LLC increased its holdings in Cellebrite DI by 2.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company's stock worth $597,000 after acquiring an additional 970 shares in the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.